Compare MTSI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTSI | VTRS |
|---|---|---|
| Founded | 1950 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1B | 18.7B |
| IPO Year | 2011 | 2019 |
| Metric | MTSI | VTRS |
|---|---|---|
| Price | $282.92 | $18.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $257.60 | $13.50 |
| AVG Volume (30 Days) | 1.2M | ★ 7.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.52 | 0.05 |
| Revenue | $967,258,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $23.55 | $4.41 |
| Revenue Next Year | $17.74 | $1.96 |
| P/E Ratio | ★ $110.54 | $365.40 |
| Revenue Growth | ★ 32.58 | N/A |
| 52 Week Low | $123.86 | $9.69 |
| 52 Week High | $418.90 | $18.39 |
| Indicator | MTSI | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 70.17 |
| Support Level | $256.10 | $15.94 |
| Resistance Level | $289.34 | $18.23 |
| Average True Range (ATR) | 10.98 | 0.42 |
| MACD | 3.06 | 0.15 |
| Stochastic Oscillator | 88.17 | 87.28 |
MACOM Technology Solutions Holdings Inc is a provider of analog, digital, and mixed-signal semiconductor solutions to original equipment manufacturers and distributors. These solutions are found in systems for industrial, medical, scientific, and test and measurement markets. The firm's portfolio of products includes integrated circuits, multichip modules, power pallets and transistors, diodes, amplifiers, switches and switch limiters, passive and active components, and complete subsystems.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.